Literature DB >> 1814618

Synthesis and biological activities of lipid A analogs: modification of a glycosidically bound group with chemically stable polar acidic groups and lipophilic groups on the disaccharide backbone with tetradecanoyl or N-dodecanoylglycyl groups.

T Kusama1, T Soga, Y Ono, E Kumazawa, E Shioya, K Nakayama, K Uoto, Y Osada.   

Abstract

Six novel lipid A analogs were synthesized. The first two analogs, 4 and 5, have an alpha-glycosidically bound carboxymethyl or 1,3-dicarboxyisopropyl group on the disaccharide backbone with four tetradecanoyl groups. The next three analogs, 6, 7 and 8, have two or four N-dodecanoylglycyl groups on the 1-alpha-O-phosphonooxyethylated disaccharide backbone. Analog 6 bears N-dodecanoylglycyl groups on the hydroxyl functions at positions 3 and 3', and tetradecanoyl groups on the amino functions at positions 2 and 2'. Analog 7 is a 2, 3, 2' and 3'-tetrakis(N-dodecanoylglycyl) derivative, and analog 8 resembles compound 6, but the binding of the N-dodecanoylglycyl and tetradecanoyl groups at positions 2, 2' and 3, 3' are reversed. The third analog, 9, has the same acyl group configuration as compound 6, but has a 1,3-dicarboxyisopropyl group at position C-1. Compounds 4 and 5 exhibited definite antitumor activity against Meth A fibrosarcoma, indicating that the phosphate group at the C-1 position in lipid A could be replaced by the carboxylic acid without reducing the antitumor activity. In rabbits, compounds 6 and 9 exhibited potent antitumor activity, but their toxicity was extremely low. On the other hand, compounds 7 and 8 showed no antitumor activity. The levels of antitumor activity of 6 and 9 were similar to those of the natural-type lipid A. The antitumor activities of analogs with a N-dodecanoylglycyl group on the disaccharide backbone depended on the connecting sites of the acyl groups.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1814618     DOI: 10.1248/cpb.39.3244

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  7 in total

Review 1.  Synthesis and Glycosidation of Anomeric Halides: Evolution from Early Studies to Modern Methods of the 21st Century.

Authors:  Yashapal Singh; Scott A Geringer; Alexei V Demchenko
Journal:  Chem Rev       Date:  2022-06-08       Impact factor: 72.087

2.  Significant antitumor effect of a synthetic lipid A analogue, DT-5461, on murine syngeneic tumor models.

Authors:  E Kumazawa; A Tohgo; T Soga; T Kusama; Y Osada
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Effect of combined administration of a synthetic low-toxicity lipid A derivative, DT-5461a, and indomethacin in various experimental tumor models of colon 26 carcinoma in mice.

Authors:  T Jimbo; T Akimoto; A Tohgo
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

4.  A novel synthetic lipid A analog with low endotoxicity, DT-5461, prevents lethal endotoxemia.

Authors:  K Sato; Y C Yoo; A Fukushima; I Saiki; T A Takahashi; M Fujihara; S Tono-Oka; I Azuma
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

5.  Novel carboxylate-based glycolipids: TLR4 antagonism, MD-2 binding and self-assembly properties.

Authors:  Florent Cochet; Fabio A Facchini; Lenny Zaffaroni; Jean-Marc Billod; Helena Coelho; Aurora Holgado; Harald Braun; Rudi Beyaert; Roman Jerala; Jesus Jimenez-Barbero; Sonsoles Martin-Santamaria; Francesco Peri
Journal:  Sci Rep       Date:  2019-01-29       Impact factor: 4.379

6.  DT-5461, a new synthetic lipid A analogue, inhibits lung and liver metastasis of tumor in mice.

Authors:  K Sato; I Saiki; Y C Yoo; Y Igarashi; M Kiso; A Hasegawa; I Azuma
Journal:  Jpn J Cancer Res       Date:  1992-10

7.  Inhibition of tumor-induced angiogenesis by a synthetic lipid A analogue with low endotoxicity, DT-5461.

Authors:  K Sato; Y C Yoo; M Mochizuki; I Saiki; T A Takahashi; I Azuma
Journal:  Jpn J Cancer Res       Date:  1995-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.